Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wallis

Showing results (181-190 of 189) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 189 results.
BMC Infectious Diseases|August 5, 2016
The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosisAlison S Devonshire, Denise M O'Sullivan, Isobella Honeyborne, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
The Lancet. HIV|August 3, 2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn, Michael D Hughes, Justin Ritz, et al.
Journal of the International AIDS Society|August 30, 2022
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D Hughes, Robert Salata, et al.
American Journal of Respiratory and Critical Care Medicine|February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical TrialsEkaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
Plos One|December 31, 2015
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance TestingSoo-Yon Rhee, Michael R Jordan, Elliot Raizes, et al.
Clinical Pharmacology and Therapeutics|September 10, 2020
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of GenotypingKamunkhwala Gausi, Lubbe Wiesner, Jennifer Norman, et al.
Communications Medicine|April 17, 2026
Viral variant but not host factors associate with SARS-CoV-2 viral kineticsWilliam O Hahn, Leigh H Fisher, Amy Ward, et al.
The Journal of Infectious Diseases|May 21, 2013
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineMichele W Tang, Soo-Yon Rhee, Silvia Bertagnolio, et al.
Pageof 19

Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
BMC Infectious Diseases|August 5, 2016
The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosisAlison S Devonshire, Denise M O'Sullivan, Isobella Honeyborne, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
The Lancet. HIV|August 3, 2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn, Michael D Hughes, Justin Ritz, et al.
Journal of the International AIDS Society|August 30, 2022
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D Hughes, Robert Salata, et al.
American Journal of Respiratory and Critical Care Medicine|February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical TrialsEkaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
Plos One|December 31, 2015
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance TestingSoo-Yon Rhee, Michael R Jordan, Elliot Raizes, et al.
Clinical Pharmacology and Therapeutics|September 10, 2020
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of GenotypingKamunkhwala Gausi, Lubbe Wiesner, Jennifer Norman, et al.
Communications Medicine|April 17, 2026
Viral variant but not host factors associate with SARS-CoV-2 viral kineticsWilliam O Hahn, Leigh H Fisher, Amy Ward, et al.
The Journal of Infectious Diseases|May 21, 2013
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineMichele W Tang, Soo-Yon Rhee, Silvia Bertagnolio, et al.
Pageof 19